Health Care | Health Care Equipment & Services | Health Care Equipment & Supplies | Health Care Equipment
NASDAQ | Common Stock
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative products to address the device protection, women's health, orthobiologics, cardiovascular, and soft tissue reconstruction markets.
It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device.
The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons.
In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues.
Further, the company provides contract manufacturing services for various products to corporate customers.
It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents.
The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | -0.50 Increased by +31.51% | -0.56 Increased by +10.71% |
| Aug 14, 23 | -0.65 Increased by +5.80% | -0.29 Decreased by -124.14% |
| May 10, 23 | -0.49 Increased by +18.33% | -0.54 Increased by +9.26% |
| Mar 22, 23 | -0.38 Increased by +53.66% | -0.69 Increased by +44.93% |
| Nov 14, 22 | -0.73 Increased by +9.88% | -0.66 Decreased by -10.61% |
| Aug 11, 22 | -0.69 Decreased by -18.97% | -0.56 Decreased by -23.21% |
| May 9, 22 | -0.60 Decreased by -20.00% | -0.62 Increased by +3.23% |
| Mar 3, 22 | -0.82 Decreased by -43.86% | -0.68 Decreased by -20.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 6.13 M Decreased by -50.54% | -9.75 M Increased by +1.64% | Decreased by -159.08% Decreased by -98.88% |
| Jun 30, 23 | 10.30 M Decreased by -18.53% | -10.62 M Decreased by -13.01% | Decreased by -103.16% Decreased by -38.72% |
| Mar 31, 23 | 13.05 M Increased by +13.53% | -7.97 M Increased by +2.15% | Decreased by -61.10% Increased by +13.81% |
| Dec 31, 22 | 12.66 M Increased by +16.61% | -5.44 M Increased by +39.98% | Decreased by -42.95% Increased by +48.53% |
| Sep 30, 22 | 12.39 M Increased by +7.87% | -9.91 M Decreased by -19.17% | Decreased by -79.99% Decreased by -10.47% |
| Jun 30, 22 | 12.64 M Increased by +3.93% | -9.40 M Decreased by -294.05% | Decreased by -74.36% Decreased by -279.14% |
| Mar 31, 22 | 11.49 M Decreased by -10.78% | -8.15 M Decreased by -60.82% | Decreased by -70.89% Decreased by -80.26% |
| Dec 31, 21 | 10.86 M Decreased by -12.88% | -9.06 M Decreased by -69.23% | Decreased by -83.45% Decreased by -94.24% |